No abstract

Forty new aminoalkanol derivatives with potential anticonvulsant activity were designed and synthesized. In vivo studies (mice, intraperitoneal administration) showed anticonvulsant activity (maximal electroshock seizure test, MES test) of nineteen compounds, (ED50 values and protective indices PI ranging 22.62–78.30 mg/kg b.w. and 1.78–4.25, respectively). Compounds 30 (R,S‐1‐((2‐(2‐(2‐chloro‐5‐methylphenoxy)ethoxy)ethyl)amino)propan‐2‐ol), 31 (R,S‐2‐((2‐(2‐(2‐chloro‐5‐methylphenoxy)ethoxy)ethyl)amino)propan‐1‐ol) and 33 (S enantiomer of 31) showed relatively low ED50 values (26.45–34.26 mg/kg b.w.) accompanied by PI indexes above 3. Compounds 30 and 31 were investigated in terms of mechanism of action (5‐HT1A receptors binding assay and in silico database screening) and safety against gastrointestinal flora (both compounds proved safe). An integral part of the study was also a comprehensive structure‐activity relationship, including current and previously obtained results for aminoalkanol derivatives.